ArriVent BioPharma, Inc. Common Stock (AVBP) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -41.89M | -30.66M | -35.8M | -26.12M | -68.01M | -16.15M | -16.34M | -19.09M | -18.63M | -14.91M | -15.44M | -8.61M | -16.88M | -15.89M | -8.91M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 38.4% | -89.81% | -119.02% | -36.87% | -265.08% | -8.31% | -5.85% | -121.79% | -10.35% | 6.13% | - | - | -89.48% | - | - |
| Net Income | -43.32M | -35.54M | -34.98M | -31.4M | -64.39M | -20.63M | -20.56M | -21.87M | -17.42M | -21.19M | -14.4M | -21.57M | -12.17M | -10.44M | -7.35M |
| Depreciation & Amortization | 0 | -3.03M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 3.22M | 3.72M | 3.31M | 2.27M | 952K | 866K | 765K | 625K | 319K | 217K | 193K | 166K | 113K | 99K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 4.93M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 293K |
| Working Capital Changes | -3.5M | 4.69M | -4.54M | 1.96M | -5.89M | 3.53M | 3.35M | 2.02M | -1.84M | 5.96M | -1.26M | 12.77M | -4.88M | -5.56M | -1.95M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 2.81M | -8K | 1.87M | -302K | 582K | -865K | 834K | -346K | -374K | 295K | -2.23M | 3.69M | -380K | 19K | 0 |
| Cash from Investing | 3.58M | -71.2M | -50.76M | 13.91M | 36.82M | -192.47M | 0 | 0 | 0 | 25M | 0 | -25M | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 1.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 54.87M | 34.73M | 86.47M | 75.11M | 6.76M | 55K | 531K | 363K | 185.63M | -1.06M | -1.03M | -20K | 44.97M | 109.72M | 30M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 54.87M | 34.8M | 86.47M | 75.34M | 6.76M | 0 | 531K | 319K | 185.63M | -1.06M | -1.03M | -20K | 44.94M | 109.71M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -70K | 0 | -227K | 0 | 55K | 0 | 44K | 1K | 0 | 0 | 0 | 26K | 15K | 30M |
| Net Change in Cash | 16.56M | -67.13M | -93K | 62.9M | -24.43M | -208.56M | -15.81M | -18.72M | 167M | 9.03M | -16.48M | 157.83M | 28.09M | 93.83M | 0 |
| Free Cash Flow | -41.89M | -30.66M | -35.8M | -26.12M | -68.01M | -16.15M | -16.34M | -19.09M | -18.63M | -14.91M | -15.44M | -8.61M | -16.88M | -15.89M | -8.91M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 38.4% | -89.81% | -119.02% | -36.87% | -265.08% | -8.31% | -5.85% | -121.79% | -10.35% | 6.13% | - | - | -89.48% | - | - |
| FCF per Share | -0.93 | -0.80 | -0.85 | -0.75 | -2.01 | -0.48 | -0.49 | -0.57 | -0.56 | -0.45 | -0.46 | -0.26 | -0.50 | -0.47 | -6.98 |
| FCF Conversion (FCF/Net Income) | 0.97x | 0.86x | 1.02x | 0.83x | 1.06x | 0.78x | 0.79x | 0.87x | 1.07x | 0.70x | 1.07x | 0.40x | 1.39x | 1.52x | 1.21x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |